Dorzolamide valuable in medical treatment of glaucoma

Abstract

Glaucoma is the third most common cause of blindness in the US. Traditionally, topical β-blockers have been first-line therapy for glaucoma and ocular hypertension, with oral carbonic anhydrase inhibitors being reserved for those patients who had an insufficient response to standard therapy. With the advent of dorzolamide, which is the first topically active carbonic anhydrase inhibitor, a new therapeutic option is available. The development, pharmacology and clinical efficacy of dorzolamide was discussed at the San Diego Eye Bank-sponsored 17th Current Concepts in Ophthalmology [ San Diego, US; July 1997 ].